We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

Deep-pocketed investors have adopted a bearish approach towards BioNTech (NASDAQ:BNTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Pfizer (NYSE:PFE) shares reached a session low on Wednesday after The Wall Street Journal reported that the U.S. attorney’s ...

Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form Confirming validity of ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...